NCT02487095 2025-04-13
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
9 trialsNCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT00065182 2019-06-24
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00287963 2018-05-17
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00365547 2017-12-28
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00390806 2014-01-20
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00049998 2013-03-04
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00002537 2013-02-11
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed